Project Grant R43AI189041
Award Date
12/23/24
Completion Date
11/30/26
Dollars Obligated
$288K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Fort Detrick, MD 21702, USA
Similar Awards
This federal Project Grant award in the amount of $837,644 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop novel vaccine candidates targeting the poly-β-(1,6)-N-acetylglucosamine (PNAG) virulence factor, which is present on the surface of many non-viral pathogens. The research team will synthesize a comprehensive library of PNAG glycans with systematically...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $234,586 to Louisiana State University to conduct research on developing a bivalent glycoconjugate vaccine for preventing Acinetobacter baumannii infections. The key products and services to be delivered include: Chemical synthesis of A. baumannii glycans, including a pentasaccharide O-glycan and fragments of a...
This $569,210 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to structurally and functionally characterize three key proteins responsible for antimicrobial peptide/colistin resistance in Gram-negative bacteria, including high-threat pathogens like carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae. The research aims to develop...
The federal Project Grant award in the amount of $859,597.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV vaccine candidate. The key objective is to elicit broadly neutralizing antibody responses against the HIV-1 fusion peptide epitope using immunogens based on AB toxin B subunits, such as cholera toxin B (CTB). The award supports a multi-year research...
This $895,538 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to discover shorter and more effective oral treatment regimens for Mycobacterium abscessus pulmonary disease. The key objectives are to: Propose optimized all-oral drug regimens with the greatest potential for rapid bacterial clearance and sterilization of M. abscessus infections, based on their ability...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $950,092 to Seattle Children's Hospital (dba Seattle Children's Research Institute) to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The research aims to create an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine to improve immunity and prevent NTM...
This $2,308,174 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop new antibiotic combinations and dosing strategies to combat carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The award, which runs from August 8, 2024 to May 31, 2029, involves three projects and three cores conducted by the University of Florida, the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 project grant (R21AI185735) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant supports research focused on developing a broad-spectrum influenza vaccine by targeting the neuraminidase (NA) protein. Specifically, the project aims to evaluate recently discovered NA broadly neutralizing antibodies (bnAbs) to assess their potential for...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $802,798 to The Research Foundation For The State University Of New York (RF SUNY) to develop a novel class of antimicrobial agents called "Biamyxins" (BMX) for treating multidrug-resistant Gram-negative bacterial infections. The funding supports further optimization of the lead BMX compound...
The federal Project Grant award, totaling $745,752 and awarded on July 19, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID), supports research to develop a novel HIV-1 vaccine that can provide mucosal barrier protection. The grant is part of the NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), which funds research to advance the understanding, prevention, diagnosis, and treatment of infectious diseases and related conditions. The key focus of...